By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Improving people’s quality of life
through innovative,
sustainable, and effective pain relief
Innovation in pain relief

Breaking news

View all

Breaking new ground in pain management

July 8, 2025

Breaking new ground in pain management In the latest episode of BioBizBuzz, PharmNovo CEO Per von Mentzer sits down with host Mike Ward to discuss how we’re tackling one of modern medicine’s most urgent challenges: finding effective, non-addictive treatments for chronic and neuropathic pain. The conversation highlights the development of our lead candidate PN6047, a selective delta-opioid receptor agonist designed to deliver strong pain relief without the addiction risks or sedation associated with traditional opioids. Per shares insights into the scientific rationale, clinical potential, and why neuropathic pain—often caused by nerve damage from conditions like diabetes or chemotherapy—demands new thinking. For anyone interested in neuroscience, biotech innovation, or the future of pain management, this episode offers a glimpse into what could become a paradigm shift in treatment. Listen to the full episode here:

Read more

Breaking new ground in pain management

July 8, 2025

Breaking new ground in pain management In the latest episode of BioBizBuzz, PharmNovo CEO Per von Mentzer sits down with host Mike Ward to discuss how we’re tackling one of modern medicine’s most urgent challenges: finding effective, non-addictive treatments for chronic and neuropathic pain. The conversation highlights the development of our lead candidate PN6047, a selective delta-opioid receptor agonist designed to deliver strong pain relief without the addiction risks or sedation associated with traditional opioids. Per shares insights into the scientific rationale, clinical potential, and why neuropathic pain—often caused by nerve damage from conditions like diabetes or chemotherapy—demands new thinking. For anyone interested in neuroscience, biotech innovation, or the future of pain management, this episode offers a glimpse into what could become a paradigm shift in treatment. Listen to the full episode here:

Read more

This is Pharmnovo

PharmNovo is a Swedish pharma company based in Medicon Village, Lund. PharmNovo has developed a novel compound portfolio based on a new type of selective delta opioid receptor agonists (DORAs), intended to provide effective neuropathic pain relief without the adverse side effects of conventional opioids. The lead candidate, PN6047, is currently in the final stages of  phase I studies and PharmNovo is preparing for phase 2 studies with PN6047 in chronic neuropathic pain and potentially other diseases of the nervous system.

Read more
A woman heaving a headache
An illustration of a brain

PN6047 – a novel drug for neuropathic pain

PN6047 is a unique substance based on research by PharmNovo’s founder Bengt von Mentzer. It is shown to be potent, safe, and effective and does not affect the receptors usually known to cause addiction to conventional opioids. It also lacks the usual unwanted side effects associated with other non-selective opioids. PN6047 will shortly be entering phase II proof-of-concept studies.

Read more

pain therapy market

Neuropathic pain affects up to ten percent of the population in Europe and the United States, but the treatment of neuropathic pain is still a clearly unmet medical need. To date, there is no pain relief offered to these patients that is not associated with potentially severe side effects.

Read more
An illustration of a brain
A woman heaving a headache

PharmNovo For investors

PharmNovo will soon initiate a phase II proof of concept clinical study of the drug candidate PN6047 to show its effect on neuropathic pain conditions.

  • New type of drug with first-in-class potential
  • Pre-clinical and clinical proof of concept
  • Experienced and dedicated team
  • Sizeable high-growth market
Read more

more news

View all
March 12, 2025

Positive FDA feedback for PN6047

PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.

Read more
February 26, 2025

Pioneering approach to treat neuropathic pain

PharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.

Read more
October 25, 2024

PharmNovo live at neurology theme event at RedEye

Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.

Read more
October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

Read more